Tenax Therapeutics (TENX) Competitors $5.76 +0.01 (+0.17%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. HURA, IOBT, WHWK, OCX, VIRI, CRBP, ADAG, ENTX, ORMP, and JMACShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include TuHURA Biosciences (HURA), IO Biotech (IOBT), Whitehawk Therapeutics (WHWK), OncoCyte (OCX), Virios Therapeutics (VIRI), Corbus Pharmaceuticals (CRBP), Adagene (ADAG), Entera Bio (ENTX), Oramed Pharmaceuticals (ORMP), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors TuHURA Biosciences IO Biotech Whitehawk Therapeutics OncoCyte Virios Therapeutics Corbus Pharmaceuticals Adagene Entera Bio Oramed Pharmaceuticals Maxpro Capital Acquisition TuHURA Biosciences (NASDAQ:HURA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations. Do analysts rate HURA or TENX? TuHURA Biosciences currently has a consensus target price of $12.67, indicating a potential upside of 410.75%. Tenax Therapeutics has a consensus target price of $17.50, indicating a potential upside of 203.82%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media favor HURA or TENX? In the previous week, TuHURA Biosciences had 6 more articles in the media than Tenax Therapeutics. MarketBeat recorded 6 mentions for TuHURA Biosciences and 0 mentions for Tenax Therapeutics. Tenax Therapeutics' average media sentiment score of 0.00 beat TuHURA Biosciences' score of -0.39 indicating that Tenax Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment TuHURA Biosciences Neutral Tenax Therapeutics Neutral Is HURA or TENX more profitable? TuHURA Biosciences' return on equity of 291.69% beat Tenax Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TuHURA BiosciencesN/A 291.69% 122.09% Tenax Therapeutics N/A -31.51%-30.35% Do insiders and institutionals have more ownership in HURA or TENX? 0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, HURA or TENX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTuHURA BiosciencesN/AN/A-$21.68MN/AN/ATenax TherapeuticsN/AN/A-$17.60M-$2.48-2.32 Which has more risk & volatility, HURA or TENX? TuHURA Biosciences has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. SummaryTuHURA Biosciences beats Tenax Therapeutics on 6 of the 11 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.85M$2.87B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.04%P/E Ratio-2.3220.8027.0020.11Price / SalesN/A286.27429.45119.84Price / CashN/A41.1936.8257.86Price / Book0.217.487.985.56Net Income-$17.60M-$55.04M$3.16B$248.40M7 Day Performance0.35%2.44%2.38%4.67%1 Month Performance-1.71%1.90%2.17%6.64%1 Year Performance80.56%4.35%33.80%21.31% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.2571 of 5 stars$5.76+0.2%$17.50+203.8%+81.7%$23.85MN/A-2.329HURATuHURA Biosciences1.2298 of 5 stars$2.23+0.5%$12.67+468.0%N/A$96.97MN/A0.00N/AGap UpIOBTIO Biotech2.6461 of 5 stars$1.39-3.5%$9.33+571.5%+22.9%$94.87MN/A-0.9330News CoverageGap UpWHWKWhitehawk TherapeuticsN/A$1.87-3.1%N/AN/A$90.92M$25.98M0.0040OCXOncoCyte2.0104 of 5 stars$3.18+16.3%$6.06+90.9%+5.8%$90.80M$3.84M-0.90120Positive NewsVIRIVirios TherapeuticsN/A$4.71-1.3%$5.00+6.2%+1,782.4%$90.71MN/A-17.445CRBPCorbus Pharmaceuticals3.8097 of 5 stars$6.90-6.8%$50.88+637.3%-85.2%$90.55MN/A-1.6440ADAGAdagene2.0025 of 5 stars$1.95+1.6%$8.00+310.3%-33.0%$90.45M$100K0.00260News CoverageGap UpENTXEntera Bio2.0339 of 5 stars$1.90-4.0%$10.00+426.3%+0.6%$89.99M$180K-7.3120News CoveragePositive NewsGap UpORMPOramed Pharmaceuticals0.2597 of 5 stars$2.25+4.7%N/A-17.1%$87.83M$1.34M-5.1110JMACMaxpro Capital AcquisitionN/A$6.51+1.5%N/A+3,268.2%$87.42MN/A0.002,021 Related Companies and Tools Related Companies TuHURA Biosciences Alternatives IO Biotech Alternatives Whitehawk Therapeutics Alternatives OncoCyte Alternatives Virios Therapeutics Alternatives Corbus Pharmaceuticals Alternatives Adagene Alternatives Entera Bio Alternatives Oramed Pharmaceuticals Alternatives Maxpro Capital Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.